X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK vs NATCO PHARMA - Comparison Results

MERCK    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK NATCO PHARMA MERCK/
NATCO PHARMA
 
P/E (TTM) x 50.9 13.8 368.4% View Chart
P/BV x 8.9 2.9 308.3% View Chart
Dividend Yield % 0.4 1.5 24.7%  

Financials

 MERCK   NATCO PHARMA
EQUITY SHARE DATA
    MERCK
Dec-17
NATCO PHARMA
Mar-18
MERCK/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,3581,080 125.7%   
Low Rs933671 139.0%   
Sales per share (Unadj.) Rs665.0592.1 112.3%  
Earnings per share (Unadj.) Rs56.6188.4 30.0%  
Cash flow per share (Unadj.) Rs72.5206.3 35.1%  
Dividends per share (Unadj.) Rs15.008.25 181.8%  
Dividend yield (eoy) %1.30.9 139.0%  
Book value per share (Unadj.) Rs441.7833.6 53.0%  
Shares outstanding (eoy) m16.6036.90 45.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.71.5 116.4%   
Avg P/E ratio x20.24.6 435.6%  
P/CF ratio (eoy) x15.84.2 372.4%  
Price / Book Value ratio x2.61.1 246.8%  
Dividend payout %26.54.4 605.5%   
Avg Mkt Cap Rs m19,01132,311 58.8%   
No. of employees `0001.54.8 32.0%   
Total wages/salary Rs m1,6963,256 52.1%   
Avg. sales/employee Rs Th7,150.04,522.5 158.1%   
Avg. wages/employee Rs Th1,098.7674.0 163.0%   
Avg. net profit/employee Rs Th608.21,439.0 42.3%   
INCOME DATA
Net Sales Rs m11,04021,848 50.5%  
Other income Rs m240404 59.3%   
Total revenues Rs m11,27922,252 50.7%   
Gross profit Rs m1,3769,284 14.8%  
Depreciation Rs m264662 39.9%   
Interest Rs m0154 0.0%   
Profit before tax Rs m1,3528,872 15.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m5831,920 30.4%   
Profit after tax Rs m9396,952 13.5%  
Gross profit margin %12.542.5 29.3%  
Effective tax rate %43.121.6 199.2%   
Net profit margin %8.531.8 26.7%  
BALANCE SHEET DATA
Current assets Rs m7,52321,307 35.3%   
Current liabilities Rs m2,2535,920 38.1%   
Net working cap to sales %47.770.4 67.8%  
Current ratio x3.33.6 92.8%  
Inventory Days Days5273 71.2%  
Debtors Days Days41107 38.1%  
Net fixed assets Rs m1,24014,986 8.3%   
Share capital Rs m166369 45.0%   
"Free" reserves Rs m7,16730,353 23.6%   
Net worth Rs m7,33330,760 23.8%   
Long term debt Rs m00-   
Total assets Rs m9,91237,151 26.7%  
Interest coverage xNM58.6-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.6 189.4%   
Return on assets %9.519.1 49.5%  
Return on equity %12.822.6 56.7%  
Return on capital %20.829.3 70.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,01510,322 9.8%   
Fx outflow Rs m3,0432,978 102.2%   
Net fx Rs m-2,0287,343 -27.6%   
CASH FLOW
From Operations Rs m5374,636 11.6%  
From Investments Rs m-476-11,155 4.3%  
From Financial Activity Rs m-2206,509 -3.4%  
Net Cashflow Rs m-160-18 886.1%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 1.5 3,523.8%  
Indian inst/Mut Fund % 18.2 7.8 232.1%  
FIIs % 1.0 16.6 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 26.0 111.9%  
Shareholders   28,591 25,395 112.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare MERCK With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

NBFCs Back in Focus; WPI Inflation at 2-Year Low, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets fell sharply during the closing hours and ended deep in the red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

FM Nirmala Sitharaman Inherits an Economy Facing a Number of Headwinds(Sector Info)

Jun 4, 2019

The Indian economy is in a major slowdown. Will the new finance minister, Nirmala Sitharaman bring the much-needed reforms?

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MERCK SHARE PRICE


Jun 14, 2019 (Close)

TRACK MERCK

COMPARE MERCK WITH

MARKET STATS